We are live on ! Find out more
CWG

C WorldWide Group Portfolio holdings

AUM $4.66B
1-Year Est. Return 11.67%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+11.67%
3 Year Est. Return
+62.16%
5 Year Est. Return
+69.96%
10 Year Est. Return
+372.2%
AUM
$6.92B
AUM Growth
-$118M
Cap. Flow
-$387M
Cap. Flow %
-5.59%
Top 10 Hldgs %
73.6%
Holding
128
New
2
Increased
25
Reduced
68
Closed
5

Top Buys

Rank Stock Value
1
V icon
Visa
V
+$13.6M
2
C icon
Citigroup
C
+$10.3M
3
ECL icon
Ecolab
ECL
+$9.75M
4
AMZN icon
Amazon
AMZN
+$8.59M
5
HD icon
Home Depot
HD
+$8.35M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$300M
2
META icon
Meta Platforms (Facebook)
META
+$53.9M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$42.9M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$12.5M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.74M

Sector Composition

Rank Sector Weight
1 Financials 30.75%
2 Consumer Discretionary 19.53%
3 Communication Services 15.03%
4 Healthcare 13.85%
5 Materials 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$123B
$7.28M 0.11%
48,588
+10,442
+27% +$1.55M
ZBH icon
52
Zimmer Biomet
ZBH
$18.8B
$7.2M 0.1%
61,428
– –
JAZZ icon
53
Jazz Pharmaceuticals
JAZZ
$16.1B
$6.69M 0.1%
49,654
-297
-0.6% -$41.2K
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.64B
$5.59M 0.08%
100,478
-21,991
-18% -$1.16M
NUVA
55
DELISTED
NuVasive, Inc.
NUVA
$5.41M 0.08%
92,444
-2,383
-3% -$135K
PTLA
56
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.09M 0.07%
104,671
-18,130
-15% -$917K
BMRN icon
57
BioMarin Pharmaceuticals
BMRN
$11.9B
$5.05M 0.07%
56,680
-32,292
-36% -$2.81M
HZNP
58
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.01M 0.07%
342,894
-40,254
-11% -$565K
AERI
59
DELISTED
Aerie Pharmaceuticals
AERI
$4.91M 0.07%
82,188
-7,196
-8% -$436K
INCY icon
60
Incyte
INCY
$25.4B
$4.75M 0.07%
50,176
-25,765
-34% -$2.69M
AIMT
61
DELISTED
Aimmune Therapeutics
AIMT
$4.68M 0.07%
123,700
-107,200
-46% -$3.46M
KTWO
62
DELISTED
K2M Group Holdings, Inc
KTWO
$4.17M 0.06%
231,368
+30,176
+15% +$573K
DXCM icon
63
DexCom
DXCM
$29B
$4.11M 0.06%
286,748
+59,408
+26% +$772K
XENT
64
DELISTED
Intersect ENT, Inc
XENT
$4.08M 0.06%
125,890
-20,836
-14% -$625K
DERM
65
DELISTED
Dermira, Inc.
DERM
$3.92M 0.06%
141,062
-11,999
-8% -$318K
NVCR icon
66
NovoCure
NVCR
$1.76B
$3.85M 0.06%
190,800
-39,700
-17% -$764K
GWPH
67
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.85M 0.06%
29,190
-2,673
-8% -$314K
EXAS
68
DELISTED
Exact Sciences
EXAS
$3.85M 0.06%
73,310
-79,820
-52% -$4.26M
RARE icon
69
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.31M 0.05%
71,440
-6,251
-8% -$307K
TVRD
70
Tvardi Therapeutics
TVRD
$20.1M
$3.27M 0.05%
7,428
-665
-8% -$303K
ITCI
71
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.22M 0.05%
222,510
-19,646
-8% -$303K
OTEX icon
72
Open Text
OTEX
$6.28B
$3.1M 0.04%
69,300
+20,600
+42% +$687K
STML
73
DELISTED
Stemline Therapeutics, Inc.
STML
$3.05M 0.04%
195,437
+35,437
+22% +$474K
TJX icon
74
TJX Companies
TJX
$179B
$2.77M 0.04%
72,600
+38,400
+112% +$1.39M
TD icon
75
Toronto Dominion Bank
TD
$193B
$2.75M 0.04%
37,332
– –
1 2
3
4 5

Similar funds

ASC
Atalanta Sosnoff Capital New York $4.66B AUM 41.34% 1-Year Est. Return
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $4.64B AUM 38.78% 1-Year Est. Return
LPPI
Local Pensions Partnership Investment London, United Kingdom $4.63B AUM 13.51% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

C WorldWide Group's Q4 2017 Portfolio in Review

As of Q4 2017, C WorldWide Group held 128 positions worth $6.92B, down 1.7% from $7.04B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

C WorldWide Group withdrew a net $387M in Q4 2017, closing 5 positions and reducing 68 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $5.74M position sold in full.

By sector, the portfolio is most concentrated in Financials at 31% of assets, up from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.

Against the trend, C WorldWide Group opened a new position in Pinnacle Foods, Inc. worth $1.02M.

  • C WorldWide Group's largest Q4 2017 buy was Pinnacle Foods, Inc.: 17,200 shares worth $1.02M.
  • C WorldWide Group added most to Visa in Q4 2017, an estimated $13.6M increase.
  • C WorldWide Group's biggest Q4 2017 reduction was Gilead Sciences, cutting an estimated $300M.
  • C WorldWide Group fully exited Teva Pharmaceuticals in Q4 2017, selling an estimated $5.74M.
  • C WorldWide Group's ten largest holdings make up 74% of its $6.92B portfolio in Q4 2017.
  • C WorldWide Group opened 2 new positions and closed 5 in Q4 2017.
  • C WorldWide Group's portfolio value fell 1.7% quarter-over-quarter to $6.92B.

Based on C WorldWide Group's 13F filing for Q4 2017, filed 7 Feb 2018.